Press Room

8th Annual Drug Delivery and Formulation Summit

Start
Monday, March 27, 2017 - 09:00
End
Wednesday, March 29, 2017 - 17:00
Location: Berlin, Germany
Booth Number: 4
Spray Drying Contract Manufacturing Hovione Cork | Hovione

Hovione will be attending DFF Summit in Berlin as an official Partner.

Schedule meeting - 8th Annual Drug Delivery and Formulation Summit | Hovione

 

HOVIONE TABLE: #15

 

HOVIONE PRESENTATION

March 27, 2017

14:25 - 15:00

Room 3

On the day 1 of the conference, Hovione will have a slot under the Technology Spotlight. João Henriques (R&D Team Leader) will be presenting on Formulating Amorphous Solid Dispersions: Bridging Particle Engineering and Formulation. This presentation will focus on three main topics:

  1. Critical aspects in the downstream processing of amorphous solid dispersions
  2. Impact of spray dried material properties in final dosage forms production and performance
  3. Optimisation strategies for downstream processing of amorphous solid dispersions

 

If you would like to find more about Hovione's full range of inhalation development services, particle engineering and development by design schedule a meeting with us

Our colleague, Marcel Hogerheide will be pleased to meet you.

Marcel Hogerheide  | Hovione

Marcel Hogerheide

Head of Account Management & Business Development

 

 

DDF Summit Agenda

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026